Reeves Hollie M, Maitta Robert W
Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, United States.
Front Med (Lausanne). 2020 Dec 18;7:597734. doi: 10.3389/fmed.2020.597734. eCollection 2020.
A major challenge encountered by clinicians is differentiating presentations characterized by significant thrombocytopenia due to overlapping clinical symptoms and signs in the setting of ambiguous laboratory results. Immature platelets represent the youngest platelets that can be measured in peripheral blood by current hematology analyzers. These young platelets are larger, with higher RNA content recently released from the bone marrow. Thrombocytopenic presentations caused directly or indirectly by immune responses can lead to compensatory bone marrow responses seeking to normalize the platelet count; thus obtaining absolute immature platelet counts may be informative while triaging patients. Over the last decade, their use has expanded beyond being an early biomarker of bone marrow reconstitution post-hematopoietic stem cell transplantation to being used to establish bone marrow responses to infection and thrombocytopenias due to immune etiologies. Its accessibility as part of more detailed platelet indices obtained with routine laboratories makes it a promising option to understand the bone marrow's real-time response to disease states characterized by thrombocytopenia. This review will look at the immature platelet count as a biomarker, while presenting current attempts trying to understand how it could be used in thrombocytopenias occurring secondary to a given immune etiology.
临床医生面临的一个主要挑战是,在实验室结果不明确的情况下,由于临床症状和体征重叠,难以区分以严重血小板减少为特征的临床表现。未成熟血小板是目前血液学分析仪能够在外周血中检测到的最年轻的血小板。这些年轻血小板体积较大,含有最近从骨髓释放的较高RNA含量。由免疫反应直接或间接引起的血小板减少表现可导致骨髓产生代偿反应,试图使血小板计数恢复正常;因此,在对患者进行分诊时,获取绝对未成熟血小板计数可能会提供有用信息。在过去十年中,其用途已从造血干细胞移植后骨髓重建的早期生物标志物扩展到用于确定骨髓对感染的反应以及免疫病因导致的血小板减少症。它作为常规实验室获得的更详细血小板指标的一部分,易于获取,这使其成为了解骨髓对以血小板减少为特征的疾病状态的实时反应的一个有前景的选择。本综述将把未成熟血小板计数视为一种生物标志物,同时介绍目前试图了解其如何用于特定免疫病因继发的血小板减少症的相关尝试。